Dong, Mingze
Wang, Bao
Wei, Jessica
de O. Fonseca, Antonio H.
Perry, Curtis J.
Frey, Alexander
Ouerghi, Feriel
Foxman, Ellen F.
Ishizuka, Jeffrey J.
Dhodapkar, Rahul M.
van Dijk, David http://orcid.org/0000-0003-3911-9925
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (5R35GM143072)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (3R01AI157488)
Article History
Received: 14 November 2022
Accepted: 8 September 2023
First Online: 2 November 2023
Competing interests
: J.J.I. reports receiving consulting fees from Related Sciences, Danger Bio, Phenomic AI, Ono Pharmaceuticals, and Kronos Bio and holds equity in Danger Bio, Phenomic AI, and Kronos Bio. J.J.I. has also received research grants from AstraZeneca outside the submitted work.